NASDAQ:BIOL BIOLASE (BIOL) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free BIOL Stock Alerts $0.15 +0.00 (+2.78%) (As of 04:32 PM ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.13▼$0.1952-Week Range$0.13▼$32.09Volume611,876 shsAverage Volume4.50 million shsMarket Capitalization$4.81 millionP/E RatioN/ADividend YieldN/APrice Target$77.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get BIOLASE alerts: Email Address BIOLASE MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside52,821.0% Upside$77.00 Price TargetShort InterestHealthy1.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.33 out of 5 stars 2.0 Analyst's Opinion Amount of Analyst CoverageBIOLASE has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.90% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BIOLASE has recently decreased by 74.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for BIOLASE this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for BIOL on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.27% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 8.79% of the stock of BIOLASE is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About BIOLASE Stock (NASDAQ:BIOL)BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.Read More BIOL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOL Stock News HeadlinesApril 18, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)April 17, 2024 | msn.comBIOLASE (BIOL) Price Target Decreased by 19.68% to 11.45April 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!March 29, 2024 | markets.businessinsider.comCelsius Holdings: Strong Buy on Robust Finances and Global Expansion StrategyMarch 24, 2024 | marketwatch.comBiolase Shares Jump 27% After Upbeat 2024 Revenue GuidanceMarch 23, 2024 | seekingalpha.comBIOLASE, Inc. (BIOL) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | markets.businessinsider.comBiolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy RatingMarch 23, 2024 | finance.yahoo.comBIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call TranscriptApril 25, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!March 22, 2024 | markets.businessinsider.comWhy BIOLASE Shares Are Surging FridayMarch 22, 2024 | finance.yahoo.comQ4 2023 BIOLASE Inc Earnings CallMarch 21, 2024 | benzinga.comRecap: Biolase Q4 EarningsMarch 21, 2024 | sfgate.comBiolase: Q4 Earnings SnapshotMarch 20, 2024 | benzinga.comEarnings Preview For BiolaseFebruary 23, 2024 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Biolase (BIOL)February 22, 2024 | finanznachrichten.deBIOLASE, Inc.: Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in DentistryFebruary 22, 2024 | finance.yahoo.comBiolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in DentistryFebruary 21, 2024 | msn.comThe Toothbrush Storage Idea That Saves Valuable Counter Space In The BathroomFebruary 20, 2024 | finanznachrichten.deBIOLASE, Inc.: Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'February 20, 2024 | finance.yahoo.comBiolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'February 15, 2024 | finance.yahoo.comBIOLASE, Inc. Announces Closing of $7.0 Million Public OfferingFebruary 14, 2024 | finance.yahoo.comBIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementFebruary 13, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35%February 13, 2024 | msn.comGold Down Over 1%; Coca-Cola Posts Upbeat SalesFebruary 13, 2024 | finance.yahoo.comBIOLASE, Inc. Announces Pricing of $7.0 Million Public OfferingJanuary 29, 2024 | finanznachrichten.deBIOLASE, Inc.: Biolase Reports Unaudited Revenue Growth For Full Year 2023 And Provides Outlook For Full Year 2024January 13, 2024 | finance.yahoo.comBIOLASE, Inc. (BIOL) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Dental equipment & supplies Sub-IndustryN/A Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees157Year FoundedN/APrice Target and Rating Average Stock Price Target$77.00 High Stock Price Target$150.00 Low Stock Price Target$4.00 Potential Upside/Downside+52,821.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($32.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,630,000.00 Net Margins-41.97% Pretax Margin-41.90% Return on Equity-555.22% Return on Assets-53.10% Debt Debt-to-Equity Ratio34.06 Current Ratio1.26 Quick Ratio0.68 Sales & Book Value Annual Sales$49.16 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.08Miscellaneous Outstanding Shares32,520,000Free Float32,435,000Market Cap$4.73 million OptionableNot Optionable Beta0.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. John R. Beaver (Age 63)President, CEO & Director Comp: $377.53kMs. Jennifer Bright (Age 52)Chief Financial Officer Comp: $355.98kMr. Steven Sandor (Age 43)Chief Operating Officer Comp: $336.39kMr. Michael C. Carroll (Age 52)Corporate Secretary Key CompetitorsSonendoNYSE:SONXLeaflyNASDAQ:LFLYSunLink Health SystemsNYSE:SSYGT BiopharmaNASDAQ:GTBPOragenicsNYSE:OGENView All Competitors BIOL Stock Analysis - Frequently Asked Questions What is BIOLASE's stock price target for 2024? 0 brokerages have issued 12-month target prices for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they expect the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 52,821.0% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts. How have BIOL shares performed in 2024? BIOLASE's stock was trading at $1.1220 on January 1st, 2024. Since then, BIOL shares have decreased by 87.0% and is now trading at $0.1455. View the best growth stocks for 2024 here. Are investors shorting BIOLASE? BIOLASE saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 592,700 shares, a decline of 74.1% from the March 31st total of 2,290,000 shares. Based on an average daily trading volume, of 5,510,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.9% of the shares of the stock are short sold. View BIOLASE's Short Interest. When is BIOLASE's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BIOL earnings forecast. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings data on Thursday, March, 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. The medical technology company had revenue of $13.49 million for the quarter. BIOLASE had a negative net margin of 41.97% and a negative trailing twelve-month return on equity of 555.22%. When did BIOLASE's stock split? Shares of BIOLASE reverse split before market open on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has BIOLASE issued on next quarter's earnings? BIOLASE updated its first quarter 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.0 million-, compared to the consensus revenue estimate of $10.8 million. What is John R. Beaver's approval rating as BIOLASE's CEO? 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIOL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
